Randomized, Blinded, Multicenter, Phase 2 Study Comparing Veliparib Plus FOLFIRI ± Bevacizumab Versus Placebo Plus FOLFIRI ± Bevacizumab in Previously Untreated Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Veliparib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Sponsors AbbVie
- 14 Sep 2017 Status changed from active, no longer recruiting to completed.
- 27 Apr 2017 Planned End Date changed from 1 May 2017 to 18 Aug 2017.
- 27 Apr 2017 Planned primary completion date changed from 1 May 2017 to 19 May 2017.